Flotation

Moderna loads up $604m in IPO
AstraZeneca, Merck & Co and Alexion all scored exits as mRNA therapy developer Moderna floated in the largest biotech IPO of all time.
Mogu modulates US IPO
Tencent, Ping An and Bertelsmann-backed e-commerce platform Mogu has floated on the New York Stock Exchange in a $66.5m initial public offering.
Moderna adjusts IPO target to $521m
AstraZeneca, Merck and Alexion-backed Moderna Therapeutics has set its pricing range at $22 to $24 and would raise more than $521m if it floats at the top end.
Tuanche settles on $20m IPO
The Bertelsmann automotive e-commerce platform has priced its shares at the lower end of its range to raise $20m instead of its targeted $150m.
Babytree nurses $217m IPO
Alibaba-backed Babytree priced its shares at the foot of its range and will raise $217m at a valuation of $1.5bn, down from $2.2bn earlier this year.
Tongcheng-eLong books $180m flotation
The travel booking platform, backed by Ctrip, Dalian Wanda and Tencent, has priced shares at the bottom of its range and raised $180m in its initial public offering.
Vapotherm turns up final IPO size
The Kaiser Permanente-backed medical device producer upscaled its initial public offering to $64.4m after the underwriters took up the over-allotment option.
Weidai wades into public markets with $45m
The Hakim Unique, Shanda Interactive and Dong Yi Ri Sheng-backed lending platform raised $45m, floating in the middle of its range.

Other News

Vapotherm inhales $56m in IPO
Kaiser Permanente-backed respiratory device provider Vapotherm floated at the bottom of its range but raised $56m in its initial public offering.
Twist Bio hits public markets in $70m IPO
Illumina, WuXi PharmaTech, Kangmei and Institut Mérieux-backed synthetic DNA producer Twist Bioscience floated at the bottom of its range.
Orchard IPO bears $200m of fruit
GSK, Sphera Global and Medison-backed gene therapy developer Orchard Therapeutics raised $200m in an offering that could possibly close at $230m.
Axonics accepts $120m in initial public offering
The Legend Capital-backed sacral neuromodulation device developer floated in the middle of its range while upping the number of shares in the IPO.
Gamida Cell goes public in $50m IPO
Novartis and Access Industries were among the investors that bought $37.5m of the shares, which the cell therapy developer issued at a downgraded price.
Pintec lends itself to public listing
Sina invested $5m as online financing platform Pintec, which also counts Xiaomi as an investor, went public in a $44.3m initial public offering.

Editor's Picks

Orchard IPO bears $200m of fruit
GSK, Sphera Global and Medison-backed gene therapy developer Orchard Therapeutics raised $200m in an offering that could possibly close at $230m.
Innovent enters public markets with $421m IPO
Legend Holdings, Eli Lilly, Ping An, China Life and Taikang-backed Innovent Biologics priced its shares near the top of the range of to raise $421m.
Allogene rallies to $324m IPO
The Pfizer and Gilead-backed immuno-oncology therapy developer, which had raised $300m in an April series A round, floated at the top of its range.
Guardant Health gets to public markets with $238m
The SoftBank-backed precision oncology test developer floated above its range and saw its share price rise 69% on the first day of trading.
test reg

Login